cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Regenxbio Inc
2 own
3 watching
Current Price
$23.13
$0.13
(0.57%)
logo-rgnx
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,001.34M
52-Week High
52-Week High
35.73
52-Week Low
52-Week Low
18.69
Average Volume
Average Volume
0.3M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
44.65
iconMarket Capitalization1,001.34M
icon52-Week High35.73
icon52-Week Low18.69
iconAverage Volume0.3M
iconDividend Yield--
iconP/E Ratio44.65
What does the Regenxbio Inc do?
Developing gene therapies for rare diseases with a proprietary delivery platform.
Read More
How much money does Regenxbio Inc make?
News & Events about Regenxbio Inc.
Globe Newswire
3days ago
- Publication in Human Gene Therapy provides rationale for the use of microdystrophin expression levels as a surrogate endpoint reasonably likely to predict clinical benefit for AAV gene therapy intended for treatment of patients with Duchenne muscular dystrophy - - White paper submitted to the U.S...
PR Newswire
6days ago
REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients PR...
PR Newswire
26days ago
REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference PR Newswire ROCKVILLE, Md., Jan. 3, 2023 ROCKVILLE, Md., Jan. 3, 2023 /PRNewswire/ --REGENXBIO Inc. (Nasdaq: RGNX) today...
PR Newswire
1month ago
REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease PR Newswire ROCKVILLE, Md., Dec. 21, 2022 RGX-181 and RGX-381 are potential one-time AAV Therapeutics for the treatment of the CNS and ocular manifestations of...
PR Newswire
1month ago
REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I PR Newswire ROCKVILLE, Md., Dec. 8, 2022 RGX-111 is an investigational AAV...
Frequently Asked Questions
Frequently Asked Questions
What is Regenxbio Inc share price today?
plus_minus_icon
Can Indians buy Regenxbio Inc shares?
plus_minus_icon
How can I buy Regenxbio Inc shares from India?
plus_minus_icon
Can Fractional shares of Regenxbio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Regenxbio Inc stocks?
plus_minus_icon
What is today’s traded volume of Regenxbio Inc?
plus_minus_icon
What is today’s market capitalisation of Regenxbio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Regenxbio Inc?
plus_minus_icon
What percentage is Regenxbio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Regenxbio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$23.13
$0.13
(0.57%)
logo-rgnx
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00